Inogen (NASDAQ:INGN) Receives Hold Rating from Needham & Company LLC

Inogen (NASDAQ:INGN)‘s stock had its “hold” rating restated by equities research analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports.

Separately, StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a research report on Monday, February 10th.

Inogen Price Performance

Inogen stock opened at $9.52 on Wednesday. Inogen has a 12-month low of $5.82 and a 12-month high of $13.33. The company has a market capitalization of $226.75 million, a price-to-earnings ratio of -4.23 and a beta of 1.02. The firm’s fifty day moving average price is $10.20 and its 200 day moving average price is $10.26.

Institutional Trading of Inogen

A number of hedge funds have recently made changes to their positions in the stock. Royce & Associates LP grew its position in shares of Inogen by 499.7% in the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock worth $2,854,000 after acquiring an additional 259,308 shares in the last quarter. Prudential Financial Inc. grew its stake in Inogen by 141.5% during the 4th quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company’s stock worth $3,301,000 after buying an additional 210,961 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Inogen by 154.8% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 263,561 shares of the medical technology company’s stock worth $2,417,000 after buying an additional 160,106 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Inogen by 312.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after buying an additional 132,287 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Inogen by 25.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company’s stock valued at $5,574,000 after buying an additional 123,208 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.